Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study

References

• Wild C. World Cancer Report 2020[M]. Imprimerie Faurite. France: World Health Organization; 2020.
   Google Scholar
• Lee SW, Choi J, Kim SU, Lim Y-S. Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol. 2021;27(3):402–412. doi:10.3350/cmh.2021.0179
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Ca a Cancer J Clinicians. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2022;28(2):276–331. doi:10.3350/cmh.2022.0084
   PubMed Web of Science ®Google Scholar
• Chan HLY. Okuda lecture: challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol. 2019;34:501–506. doi:10.1111/jgh.14534
   PubMed Web of Science ®Google Scholar
• Yu JH, Cho SG, Y- J J, Lee J-W. The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. Clin Mol Hepatol. 2022;28:351–362. doi:10.3350/cmh.2021.0281
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kanwal F, Feng Z, Marrero J, Khaderi S, Singal AG. Risk factors for cirrhosis in contemporary hepatology practices-findings from the Texas hepatocellular carcinoma consortium cohort. Gastroenterology. 2020;159:376–377. doi:10.1053/j.gastro.2020.03.049
   PubMed Web of Science ®Google Scholar
• Amit GS, Emily Z, Manasa N, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(77):128–139. doi:10.1016/j.jhep.2022.01.023
   PubMedGoogle Scholar
• Marasco G, Colecchia A, Colli A, et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection[J]. J Hepatol. 2019;70(3):440–448. doi:10.1016/j.jhep.2018.10.022
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El- Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(4):4–13. doi:10.1002/hep.31288
   PubMedGoogle Scholar
• YVan der Pol CB, Lim CS, Sirlin CB, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy— a systematic review. Gastroenterology. 2019;156(4):976–986. doi:10.1053/j.gastro.2018.11.020
   PubMed Web of Science ®Google Scholar
• Liang LY, Lee HW, Wong VW, et al. Serum fibrosis index- based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol. 2021;27(3):499–509. doi:10.3350/cmh.2020.0333
   PubMed Web of Science ®Google Scholar
• Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64(8):1289–1295. doi:10.1136/gutjnl-2014-307023
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-Bpredicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitisB on 5-year antiviral therapy. J Hepatol. 2016;64:800–806. doi:10.1016/j.jhep.2015.11.035
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YD, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018;69(5):1066–1073. doi:10.1016/j.jhep.2018.07.018
   PubMed Web of Science ®Google Scholar
• Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292–302. doi:10.1002/hep.27382
   PubMed Web of Science ®Google Scholar
• Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis[J]. J Hepatol. 2018;68:92–99. doi:10.1016/j.jhep.2017.07.033
   Web of Science ®Google Scholar
• Nam JY, Sinn DH, Bae J, Jang ES, Kim JW, Jeong SH. Deep learning model for prediction of hepatocellular carcinoma in patients with HBV- related cirrhosis on antiviral therapy. JHEP Rep. 2020;2:100175. doi:10.1016/j.jhepr.2020.100175
   PubMedGoogle Scholar
• Makridakis S, Spiliotis E, Assimakopoulos V. Statistical and machine learning forecasting methods: concerns and ways forward. PloSOne. 2018;13:e0194889. doi:10.1371/journal.pone.0194889
   PubMed Web of Science ®Google Scholar
• Wu S, Kong Y, Piao H, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. Liver Int. 2018;38:1045–1054. doi:10.1111/liv.13623
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma, a 2017 update. Hepatol Int. 2017;11:317–370. doi:10.1007/s12072-017-9799-9
   PubMed Web of Science ®Google Scholar
• Cross SS, Harrison RF, Kennedy RL. Introduction to neural networks. Lancet. 1995;346(8982):1075–1079. doi:10.1016/S0140-6736(95)91746-2
   PubMed Web of Science ®Google Scholar
• Baxt WG. Application of artificial neural networks to clinical medicine. Lancet. 1995;346(8983):1135–1138. doi:10.1016/S0140-6736(95)91804-3
   PubMed Web of Science ®Google Scholar
• Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index, A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. 2017;S0168-8278(17):32248.
   Google Scholar
• Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773–780. doi:10.1016/j.jhep.2015.11.012
   PubMed Web of Science ®Google Scholar
• Research EO, European Association for the Study of the Liver. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943. doi:10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. doi:10.1002/hep.28156
   PubMed Web of Science ®Google Scholar
• Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017;65(4):1196–1205. doi:10.1002/hep.28895
   PubMed Web of Science ®Google Scholar
• Heleno B, Thomsen MF, Rodrigues DS, Jørgensen KJ, Brodersen J. Quantification of harms in cancer screening trials: literature review. BMJ. 2013;347(sep16 1):f5334. doi:10.1136/bmj.f5334
   PubMedGoogle Scholar
• Goossens N, Singal AG, King LY, et al. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol. 2017;8:e101. doi:10.1038/ctg.2017.26
   PubMed Web of Science ®Google Scholar
• Wang JH, Chang KC, Kee KM, et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108(3):416–424. doi:10.1038/ajg.2012.445
   PubMed Web of Science ®Google Scholar